abstract |
A chimeric antisense compound having enhanced in vivo efficacy. In an animal in need of reducing target RNA expression, the use of a gap extended antisense oligonucleotide 18-24 nucleotides in the manufacture of a medicament for reducing target RNA expression, wherein: The antisense oligonucleotide comprises a gap region having more than 11 consecutive 2′-deoxyribonucleotides, and a first wing region and a second wing region adjacent to the gap region, wherein the first wing Use, wherein each of the region and the second wing region independently has 1 to 8 2'-O- (2-methoxyethyl) ribonucleotides. [Selection figure] None |